A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement?

被引：0

作者：

Paolo Antonetti

Maria Concetta Fargnoli

Giampiero Porzio

Lisa Salvatore

Roberto Filippi

Michele Ghidini

Olga Nigro

Fabio Gelsomino

Ina Valeria Zurlo

Emanuela Dell’Aquila

Pasquale Lombardi

Susana Roselló Keränen

Ilaria Depetris

Riccardo Giampieri

Cristina Morelli

Michele De Tursi

Francesca Romana Di Pietro

Nicoletta Zanaletti

Pasquale Vitale

Ingrid Garajova

Gian Paolo Spinelli

Federica Zoratto

Michela Roberto

Angelica Petrillo

Giacomo Aimar

Alessio Cortellini

Maria Vittoria Pensieri

Corrado Ficorella

Claudio Ferri

Alessandro Parisi

机构：

[1] Dermatology,Department of Biotechnological and Applied Clinical Sciences

[2] St. Salvatore Hospital,Medical Oncology, Comprehensive Cancer Center

[3] University of L’Aquila,Department of Oncology

[4] Medical Oncology,Centro Oncologico Ematologico Subalpino

[5] St. Salvatore Hospital,Department of Oncology and Hematology

[6] Università Cattolica del Sacro Cuore,Department of Medical Oncology, Hospital Clínico Universitario de Valencia, INCLIVA Biomedical Research Institute

[7] Fondazione Policlinico Universitario Agostino Gemelli,Clinica Oncologica e Centro Regionale di Genetica Oncologica

[8] IRCCS,Medical Oncology Unit and PhD program in Systems and Experimental Medicine (XXXV cycle)

[9] University of Turin,Department of Medical, Oral and Biotechnological Sciences and Center for Advance Studies and Technology (CAST)

[10] Division of Medical Oncology,Department of Precision Medicine

[11] Candiolo Cancer Institute,Department of Clinical and Molecular Medicine

[12] FPO – IRCCS,Department of Life, Health and Environmental Sciences

[13] Azienda Universitaria Ospedaliera Città della Salute e della Scienza di Torino,undefined

[14] Medical Oncology Unit,undefined

[15] Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico,undefined

[16] Medical Oncology,undefined

[17] ASST Sette Laghi,undefined

[18] Ospedale di Circolo e Fondazione Macchi,undefined

[19] Division of Oncology,undefined

[20] University Hospital of Modena,undefined

[21] Medical Oncology,undefined

[22] “Vito Fazzi” Hospital,undefined

[23] Medical Oncology 1,undefined

[24] IRCCS Regina Elena National Cancer Institute,undefined

[25] University of Valencia,undefined

[26] CIBERONC,undefined

[27] Instituto de Salud Carlos III,undefined

[28] Medical Oncology,undefined

[29] ASL TO4,undefined

[30] Ospedale Civile di Ivrea,undefined

[31] Università Politecnica delle Marche,undefined

[32] AOU Ospedali Riuniti,undefined

[33] Tor Vergata University Hospital,undefined

[34] G. D’Annunzio University,undefined

[35] Clinical Oncology Unit,undefined

[36] S.S. Annunziata Hospital,undefined

[37] IRCCS Istituto Dermopatico dell’Immacolata (IDI),undefined

[38] Experimental Clinical Abdominal Oncology Unit,undefined

[39] Istituto Nazionale Tumori-IRCCS-Fondazione G.Pascale,undefined

[40] Università della Campania “Luigi Vanvitelli”,undefined

[41] Medical Oncology Unit,undefined

[42] Santa Chiara Hospital,undefined

[43] Medical Oncology Unit,undefined

[44] University Hospital of Parma,undefined

[45] UOC Territorial Oncology - AUSL Latina-CdS Aprilia – University of Rome “Sapienza”,undefined

[46] Medical Oncology,undefined

[47] Santa Maria Goretti Hospital,undefined

[48] Sapienza University of Rome,undefined

[49] Oncology Unit,undefined

[50] Sant’Andrea Hospital,undefined

来源：

Supportive Care in Cancer | 2022年 / 30卷

关键词：

mCRC; Acneiform rash; Pre-emptive; Reactive; Paronychia; Panitumumab; Cetuximab; Anti-EGFR;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：2455 / 2465

页数：10

共 50 条

[21] The Best. First. Anti-EGFR before anti-VEGF, in the first-line treatment of RAS wild-type metastatic colorectal cancer: from bench to bedside
A. Zaniboni
V. Formica
Cancer Chemotherapy and Pharmacology, 2016, 78 : 233 - 244
[22] The Best. First. Anti-EGFR before anti-VEGF, in the first-line treatment of RAS wild-type metastatic colorectal cancer: from bench to bedside
Zaniboni, A.
Formica, V.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (02) : 233 - 244
[23] Post-induction Strategies in Metastatic Colorectal Cancer Patients Treated With First-Line Anti-EGFR-Based Treatment: A Systematic Review and Meta-Analysis
Parisi, Alessandro
Ghidini, Michele
Giampieri, Riccardo
Tomasello, Gianluca
Luciani, Andrea
Ferri, Claudio
Berardi, Rossana
Petrelli, Fausto
CLINICAL COLORECTAL CANCER, 2022, 21 (03) : E162 - E170
[24] Tumor sidedness and efficacy of first-line therapy in patients with RAS/BRAF wild-type metastatic colorectal cancer: A network meta-analysis
Wu, Chih-Chien
Wang, Jui-Ho
Lin, Pei-Chin
Liang, Chun-An
Huang, Ching-Ying
Lien, Han-Chu
Chen, Chung-Yu
Chou, Kang-Ju
Su, Yi-Chia
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2020, 145
[25] MicroRNA profiling predicts survival in anti-EGFR treated chemorefractory metastatic colorectal cancer patients with wild-type KRAS and BRAF
Mosakhani, Neda
Lahti, Leo
Borze, Ioana
Karjalainen-Lindsberg, Marja-Liisa
Sundstrom, Jari
Ristamaki, Raija
Osterlund, Pia
Knuutila, Sakari
Sarhadi, Virinder Kaur
CANCER GENETICS, 2012, 205 (11) : 545 - 551
[26] Phase II study of anlotinib in combination with oxaliplatin and capecitabine for patients with RAS/BRAF wild-type metastatic colorectal adenocarcinoma as the first-line therapy
Liu, Yue
Xiao, Qian
He, Jinjie
Hu, Hanguang
Du, Jinlin
Zhu, Yuping
Chen, Jiaqi
Liu, Zhuo
Wang, Jianping
Sun, Lifeng
Xu, Dong
Li, Jun
Liao, Xiujun
Wang, Jianwei
Cai, Yibo
Cai, Cheng
Jin, Zhekang
Wang, Liuhong
Yuan, Ying
Ding, Kefeng
BMC MEDICINE, 2022, 20 (01)
[27] Survival benefit of metastasectomy in first-line cetuximab therapy in patients with RAS wild-type metastatic colorectal cancer: a nationwide registry
Chen, Chou-Chen
Chang, Shih-Ching
Chang, Yu-Yao
Lin, Bo-Wen
Chen, Hong-Hwa
Hsieh, Yao-Yu
Hsu, Hung-Chih
Hsieh, Meng-Che
Ke, Tao-Wei
Kuan, Feng-Che
Wu, Chih-Chien
Lu, Wei-Chen
Su, Yu-Li
Liang, Yi-Hsin
Chen, Joe-Bin
Huang, Hsuan-Yuan
Tsai, Hsiang-Lin
Wang, Jaw-Yuan
AMERICAN JOURNAL OF CANCER RESEARCH, 2023, 13 (12):
[28] Epidermal growth factor inhibitors in first-line for metastatic colorectal cancer with ras wild-type: a perspective based on pharmacological costs
Giuliani, Jacopo
Bonetti, Andrea
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2017, 17 (03) : 243 - 248
[29] FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis
Chen, Datian
Li, Li
Zhang, Xiang
Gao, Guangyi
Shen, Lili
Hu, Jing
Yang, Mi
Liu, Baorui
Qian, Xiaoping
MEDICINE, 2018, 97 (10)
[30] First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis
Bobo Zheng
Xin Wang
Mingtian Wei
Quan Wang
Jiang Li
Liang Bi
Xiangbing Deng
Ziqiang Wang
BMC Cancer, 19

← 1 2 3 4 5 →